Alunacedase alfa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Alunacedase alfa
Accession Number
DB15736
Description

Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Recombinant Enzymes
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Alunacedase alfa
  • Recombinant Human Angiotensin-Converting Enzyme 2
  • rhACE2
External IDs
  • APN-01
  • APN01
  • GSK-2586881
  • GSK2586881

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action

Angiotensin Converting Enzyme 2 (ACE2) degrades Angiotensin II (known as Ang1-8) into Ang1-7. Angiotensin II exerts actions like inflammation, ROS production, and vasoconstriction, and is implicated in acute respiratory distress syndrome (ARDS). Its conversion to Ang1-7 by ACE2 contrasts these actions as Ang1-7 promotes vasodilation, anti-inflammation, and NO release -- attenuating tissue injury which includes ARDS-associated injury. Additional administration of ACE2 by way of a recombinant protein is thought to aid in conversion of excessive Ang1-8 associated with ARDS into Ang1-7, and help reduce the damaging effects of the renin-angiotensin system. This compound, as such, is being investigated for lung injury and ARDS associated with COVID-19.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
FA2I4Z873U
CAS number
2416824-55-8

References

General References
  1. Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco JJ, Tidswell M, Hardes K, Powley WM, Wright TJ, Siederer SK, Fairman DA, Lipson DA, Bayliffe AI, Lazaar AL: A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017 Sep 7;21(1):234. doi: 10.1186/s13054-017-1823-x. [PubMed:28877748]
  2. Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Krahenbuhl S: Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013 Sep;52(9):783-92. doi: 10.1007/s40262-013-0072-7. [PubMed:23681967]
  3. NCBI MedGen: Recombinant Human Angiotensin Converting Enzyme 2 APN01 [Link]
  4. Phase 2 Clinical Trial of APN01 for Treatment of COVID-19 Inititated [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAcute Lung Injury (ALI)1
2CompletedTreatmentCoronavirus Disease 2019 (COVID‑19)1
2CompletedTreatmentPulmonary Hypertension (PH)1
1CompletedTreatmentCancer Diseases / Cardiovascular Disease (CVD) / Kidney Diseases / Pulmonary Diseases1
1Not Yet RecruitingOtherCoronavirus Disease 2019 (COVID‑19) / COVID 191
1TerminatedTreatmentHealthy Volunteers1
Not AvailableWithdrawnTreatmentCoronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 20:25 / Updated on February 21, 2021 18:55